TENTANG EPISODE INI
4basebio PLC (AIM:4BB, FRA:8L7, ETR:88Q) CEO Amy Walker joined Proactive's Stephen Gunnion to discuss the company's synthetic DNA platform, growing commercial momentum and key milestones for investors.
Walker explained how 4basebio's enzyme-based technology provides a cleaner, faster and more cost-effective alternative to conventional plasmid DNA manufacturing, supporting applications in cell and gene therapy, vaccines and gene editing. She also highlighted the launch of the company's single-stranded DNA product, which offers lower toxicity and the ability to produce longer DNA molecules for advanced gene editing.
The interview also covers a recent Phase 2 clinical supply agreement, the appointment of mRNA expert Jeff Coller to the Strategic Advisory Board, expansion of the company's Cambridge manufacturing facility and the commercial milestones investors should watch for over the coming months.
For more interviews and market insights, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content.
#4basebio #SyntheticDNA #DNAManufacturing #GeneEditing #CRISPR #CellTherapy #GeneTherapy #Biotech #Biotechnology #LifeSciences #mRNA #Vaccines #PersonalizedMedicine #CancerVaccines #HealthcareInnovation #ClinicalTrials #CambridgeBiotech #Investing #SmallCapStocks #ProactiveInvestors
Walker explained how 4basebio's enzyme-based technology provides a cleaner, faster and more cost-effective alternative to conventional plasmid DNA manufacturing, supporting applications in cell and gene therapy, vaccines and gene editing. She also highlighted the launch of the company's single-stranded DNA product, which offers lower toxicity and the ability to produce longer DNA molecules for advanced gene editing.
The interview also covers a recent Phase 2 clinical supply agreement, the appointment of mRNA expert Jeff Coller to the Strategic Advisory Board, expansion of the company's Cambridge manufacturing facility and the commercial milestones investors should watch for over the coming months.
For more interviews and market insights, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content.
#4basebio #SyntheticDNA #DNAManufacturing #GeneEditing #CRISPR #CellTherapy #GeneTherapy #Biotech #Biotechnology #LifeSciences #mRNA #Vaccines #PersonalizedMedicine #CancerVaccines #HealthcareInnovation #ClinicalTrials #CambridgeBiotech #Investing #SmallCapStocks #ProactiveInvestors
Inggris
Amerika Serikat
TRANSKRIP 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
CARI EPISODE TERDAHULU
Cari episode sebelumnya dari Proactive - Interviews for investors.
EPISODE LAIN DALAM PODCAST INI
Foresight Environmental Infrastructure (LSE:FGEN) investment manager Ed Mountney spoke with Proactive's Stephen Gunnion about the company’s £104 million sale of its remaining 49% stake in six anaerobic digestion plants, debt reduction and plans to reinvest in environmental infrastructure.
Mountney…
Great Red Lake Gold Corp Chief Financial Officer Brian Morales joined Steve Darling from Proactive to discuss the company's move into copper exploration, its acquisition of the Bilton-Brown property in Ontario and plans to advance the project toward a potential drilling program in 2027.
Morales ex…
Empire Metals (AIM: EEE, ASX: EEE) managing director Shaun Bunn spoke with Proactive's Stephen Gunnion about progress towards pilot-scale testing at its Pitfield Titanium Project in Western Australia, plans to produce high-purity titanium dioxide and the next steps towards development.
Bunn explai…
Matrix Critical Minerals Limited executive chairman Chris Gibbs spoke with Proactive's Stephen Gunnion about the company’s planned IPO, the potential of its Narraburra Rare Earths Project in New South Wales, and efforts to engage strategic partners and offtake customers.
Matrix is being spun out o…
Blockmate Ventures Chairman Domenic Carosa joined Steve Darling from Proactive to announce that the company has entered into a binding agreement with Scannit Inc. to acquire its first NVIDIA B200 AI compute node, marking its entry into the AI neocloud and GPU computing market.
Under the agreement …
Sanggahan: Podcast dan karya seni yang disematkan pada halaman ini berasal dari Proactive, yang merupakan milik pemiliknya dan tidak berafiliasi atau didukung oleh Listen Notes, Inc.
Sunting
Terima kasih telah membantu agar basis data podcast tetap terbaru
